Shots:

• The P-II (innovaTV 207) trial evaluates tisotumab vedotin as monothx. in 532 patients with SCCHN who experienced disease progression & 1L Pt-containing regimen & checkpoint inhibitor
• The results showed a manageable safety profile & promising preliminary antitumor activity with the 1EPs of ORR (16%). The 2EPs included DCR, PFS/investigator (58.1%) & OS, m-PFS (4.2mos.) with a median follow-up (10.0mos.), m-OS (9.4mos.), AEs were consistent with the known safety profile of tisotumab vedotin
• Additionally, 67.7% of patients has grade ≥3 TEAEs, treatment-emergent SAEs & treatment-related SAEs (51.6% & 6.5%). The therapy has received accelerated approval for cervical cancer in Sept 2021

 Ref: Globe Newswire | Image: Businesswire